Author

Magda Conway

Observed name: Conway, Magda

Institution: PENTA Foundation

Observed institution: PENTA Foundation

OpenAlex ID: A5005904727

Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice

2025 · Nina Gobat, Catherine Slack, et al. · The Lancet Global Health · 65

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

2019 · Martina Penazzato, Claire L Townsend, et al. · The Lancet HIV · 53

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 36

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 24

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 14

Health Equity in Pediatric Drug Development: Translating Aspiration into Operation

2022 · Morenike Oluwatoyin Folayan, Magda Conway, et al. · Therapeutic Innovation & Regulatory Science · 14

D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years

2024 · Anna Turkova, Man K. Chan, et al. · Contemporary Clinical Trials · 8

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

2026 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 3

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

2025 · Lisanne A.H. Bevers, Gabriela Toledo, et al. · EBioMedicine · 3

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2

The patients'/parents' voice within pediatric drug research

2024 · Begoña Nafria Escalera, Sarah Bernays, et al. · Elsevier eBooks · 1

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV

Short-Cycle Therapy (Weekends-Off) on Dolutegravir-Based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Randomised, Open-Label, 96-Week Non-Inferiority Trial

2025 · Adeodata R. Kekitiinwa, Angus Jennings, et al. · SSRN Electronic Journal

PA-257 ‘Nothing about us without us’: multi-country adolescent patient-led recruitment information in the long-acting treatment in adolescents (LATA) trial – an animated video to compliment ‘traditional’ participant information

2023 · Magda Conway, Lungile Jafta, et al. · BMJ Global Health

The Power of Peers: Self-Stigma Impacts, Peer Support and Engagement

2016 · Magda Conway · Cross-cultural research in health, illness and well-being

Works count: 18

Citation count: 223

H-index: 7

I10-index: 6